Kishu Ranjan, PhD, of Yale University School of Medicine, discusses his study findings, which identified a deficiency in the biomarker TAP2 as a prominent immune evasion mechanism in patients whose non–small cell lung cancer has resisted immunotherapy.
Non–Small Cell Lung Cancer: New Findings on a Biomarker and Immunotherapy Resistance
November 10, 2022
by The ASCO post